Use of thiols and implications for the use of inhaled corticosteroids in the presence of oxidative stress in COPD

Respiratory Research

Table 2 Summary of ICS use data in pivotal studies of NAC, S-CMC and erdosteine in COPD

Study [Ref]	BRONCUS [99]	PANTHEON [93]	PANTHEON post-hoc [100]	PEACE [94]	RESTORE [95]	RESTORE post-hoc [101]
Mucolytic	N-acetylcysteine	N-acetylcysteine	N-acetylcysteine	Carbocysteine	Erdosteine	Erdosteine
Daily dose used	600 mg	1200 mg	1200 mg	1500 mg	600 mg	600 mg
Approved daily dose	600 mg	600 mg	600 mg	1500 mg	600 mg	600 mg
Study population	European	Chinese	Chinese	Chinese	European	European
Patients treated with ICS in the study, %	69.7	51.9	51.9	16.7	72.4	76.0
Efficacy of mucolytic irrespective of ICS use	NO	YES	NO	YES	YES	YES
Effect of mucolytic on exacerbation rate	Only in ICS non-users	YES	Only in ICS non-users	YES	YES	YES
Effect of mucolytic on exacerbation duration	No data	YES	No data	No data	YES	YES

ISSN: 1465-993X